TRANSPORT OF A CASPASE INHIBITOR ACROSS THE BLOOD BRAIN BARRIER BY CHITOSAN NANOPARTICLES


YEMISCI M., GURSOY-OZDEMIR Y., CABAN S., BODUR E., ÇAPAN Y., DALKARA T.

NANOMEDICINE: CANCER, DIABETES, AND CARDIOVASCULAR, CENTRAL NERVOUS SYSTEM, PULMONARY AND INFLAMMATORY DISEASES, vol.508, pp.253-269, 2012 (SCI-Expanded) identifier identifier

Abstract

The current treatment of neurological and psychiatric diseases is far beyond being satisfactory. In addition to highly complex disease mechanisms, the blood brain barrier (BBB) also remains as a challenge by limiting the delivery of the majority of currently available therapeutics to the central nervous system. Several approaches taking advantage of molecular and physicochemical characteristics of the BBB have been developed recently to improve drug delivery to the brain.